Ivan Bergstein
Vorstandsvorsitzender bei STEMLINE THERAPEUTICS, INC.
Aktive Positionen von Ivan Bergstein
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Vorstandsvorsitzender | - | - |
Gründer | 08.08.2003 | - | |
Präsident | 08.08.2003 | - | |
Direktor/Vorstandsmitglied | - | - | |
Vorsitzender | 08.08.2003 | 10.06.2020 | |
Unternehmenssekretär | 08.08.2003 | 18.02.2014 | |
Treasurer | 08.08.2003 | 18.02.2014 | |
Trading-Fixed Income | 08.08.2003 | 08.08.2003 | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Vorsitzender | 01.11.2021 | - |
Karriereverlauf von Ivan Bergstein
Ehemalige bekannte Positionen von Ivan Bergstein
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Nitron Advisors
Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Corporate Officer/Principal | - | - |
KERYX BIOPHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | - | - |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Ivan Bergstein
University of Pennsylvania | Undergraduate Degree |
Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Chairman | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
Nitron Advisors
Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Finance |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Ivan Bergstein
- Erfahrung